Prognosis and immunological characteristics of HDAC family in pan-cancer through integrative multi-omic analysis

被引:0
作者
Chen, Changsheng [1 ,2 ,3 ]
Wang, Ke [4 ]
Zhang, Yu [1 ,2 ,5 ]
Qi, Yixin [4 ]
Shen, Chong [1 ,2 ]
Zhang, Zhe [1 ,2 ]
Zhang, Zongliang [4 ]
Yang, Han [4 ]
Hu, Hailong [1 ,2 ]
机构
[1] Tianjin Med Univ, Hosp 2, Tianjin Inst Urol, Dept Urol, 23 Pingjiang Rd, Tianjin 300211, Peoples R China
[2] Tianjin Med Univ, Hosp 2, Tianjin Inst Urol, Tianjin Key Lab Urol, Tianjin 300211, Peoples R China
[3] Tianjin Haihe Hosp, Dept Urol, Tianjin 300350, Peoples R China
[4] Qingdao Univ, Affiliated Hosp, Dept Urol, 1677 Wutaishan Rd, Qingdao 266001, Peoples R China
[5] Tianjin Fifth Cent Hosp, Ecoc Hosp, Dept Urol, Tianjin 300451, Peoples R China
关键词
Histone deacetylase; Pan-cancer; Prognosis; Immunotherapy; Immune infiltration; HISTONE DEACETYLASES; EXPRESSION; CARCINOMAS; INHIBITORS; CELLS; CELLMINER; RESPONSES; SURVIVAL; THERAPY;
D O I
10.1186/s43042-024-00518-1
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background The histone deacetylase (HDAC) family plays a significant role in a variety of biological processes related to cancer, such as metabolism and cancer progression, and recognized as a target of anti-cancer drugs. Nevertheless, there has been limited systematic research available regarding HDAC family in human cancers using multi-omics approaches.Objective To evaluate the prognostic implications and immunological features of the HDAC family across multiple cancer types through comprehensive multi-omics analysis.Methods We studied the associations of HDAC activity and a variety of factors, encompassing immune checkpoint genes, the tumor microenvironment (TME), instability of microsatellites (MSI), inherited mutations, variation in copy number, tumor mutation burden (TMB), and sensitivity to drugs in a variety of cancer types. Moreover, we analyzed the link between the degree of HDAC activity and the effectiveness of immunotherapy in several cohorts, providing significant details about the possible impact of HDACs on immunotherapeutic responses. Furthermore, we explored potential signaling pathways of HDACs in bladder cancer (BC) using gene set enrichment analysis (GSEA). Immune infiltration analysis in bladder cancer was performed based on HDACs expression, copy number or somatic mutations. Furthermore, the Human Protein Atlas (HPA) dataset has been used to validate the expression of the HDACs protein in BC.Results The HDACs expression exhibits significant heterogeneity across different cancer types and is significantly correlated with patient prognosis, clinical traits, mutations, TME, TMB, MSI, immune checkpoint genes, and objective responses in immunotherapy. The drug sensitivity of cancers was found to be correlated with the gene expression of specific HDAC familial members. In BC, GSEA demonstrates enrichment of multiple immune-related functions and pathways; moreover, there are significant associations between genomic variations in HDACs and the degree of typical immunological cell recruitment. Furthermore, findings from differential expression analysis in BC are validated by protein expression analysis obtained from the HPA database.Conclusions These findings reveal the significance of HDAC family in survival prognosis and treatment guidance of human cancers, and some of them have the potential to be used as immunotherapy biomarkers.
引用
收藏
页数:23
相关论文
共 65 条
[1]   Histone Modifications and Cancer [J].
Audia, James E. ;
Campbell, Robert M. .
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY, 2016, 8 (04)
[2]   Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy [J].
Banik, Debarati ;
Moufarrij, Sara ;
Villagra, Alejandro .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (09)
[3]   The Substrate Specificity of Sirtuins [J].
Bheda, Poonam ;
Jing, Hui ;
Wolberger, Cynthia ;
Lin, Hening .
ANNUAL REVIEW OF BIOCHEMISTRY, VOL 85, 2016, 85 :405-429
[4]   Magnetic Solid Nanoparticles and Their Counterparts: Recent Advances towards Cancer Theranostics [J].
Cerqueira, Monica ;
Belmonte-Reche, Efres ;
Gallo, Juan ;
Baltazar, Fatima ;
Banobre-Lopez, Manuel .
PHARMACEUTICS, 2022, 14 (03)
[5]   Targeted Engineering of Medicinal Chemistry for Cancer Therapy: Recent Advances and Perspectives [J].
Chen, Weihua ;
Sun, Zhen ;
Lu, Lehui .
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2021, 60 (11) :5626-5643
[6]   Immunological Consequences of Epithelial-Mesenchymal Transition in Tumor Progression [J].
Chockley, Peter J. ;
Keshamouni, Venkateshwar G. .
JOURNAL OF IMMUNOLOGY, 2016, 197 (03) :691-698
[7]   Multiple roles of HDAC inhibition in neurodegenerative conditions [J].
Chuang, De-Maw ;
Leng, Yan ;
Marinova, Zoya ;
Kim, Hyeon-Ju ;
Chiu, Chi-Tso .
TRENDS IN NEUROSCIENCES, 2009, 32 (11) :591-601
[8]   Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis [J].
Conforti, Fabio ;
Pala, Laura ;
Bagnardi, Vincenzo ;
De Pas, Tommaso ;
Martinetti, Marco ;
Viale, Giuseppe ;
Gelber, Richard D. ;
Goldhirsch, Aron .
LANCET ONCOLOGY, 2018, 19 (06) :737-746
[9]   Histone Deacetylase Inhibitors in the Treatment of Muscular Dystrophies: Epigenetic Drugs for Genetic Diseases [J].
Consalvi, Silvia ;
Saccone, Valentina ;
Giordani, Lorenzo ;
Minetti, Giulia ;
Mozzetta, Chiara ;
Puri, Pier Lorenzo .
MOLECULAR MEDICINE, 2011, 17 (5-6) :457-465
[10]   Histone deacetylases (HDACs): characterization of the classical HDAC family [J].
De Ruijter, AJM ;
Van Gennip, AH ;
Caron, HN ;
Kemp, S ;
Van Kuilenburg, ABP .
BIOCHEMICAL JOURNAL, 2003, 370 :737-749